DIA Biosimilars 2013

Adeona Pharmaceuticals

Adeona's reaZin study meets primary outcomes

Friday, April 15, 2011 12:32 PM

Adeona Pharmaceuticals, a developer of medicines for CNS diseases, has results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The clinical study met the primary outcome of increasing serum zinc and decreasing serum free copper. In addition, secondary outcomes of mental status as measured by three standardized cognitive tests all favored the treatment group versus the placebo group.

More... »

Cenduit: Now with Patient Reminders

Dr. Ashley I. Bush joins Adeona's scientific advisory board

Friday, April 1, 2011 11:16 AM

ANN ARBOR, Mich.-based Adeona Pharmaceuticals, a developer of medicines for serious central nervous system diseases, announced that Ashley I. Bush, M.D., Ph.D., has joined the company's scientific advisory board.

More... »

CRF Health – eCOA Forum

Adeona names Brewer senior vice president of R&D

Wednesday, March 9, 2011 10:56 AM

Adeona Pharmaceuticals, a developer of medicines for serious central nervous system diseases, has appointed George J. Brewer, M.D., senior vice president of R&D.  Dr. Brewer joins the Adeona management team after serving as chairman of the company's scientific advisory board for seven years.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs